Evidence map›Paper›PMID 34527210›Full record

ArticleMediterranean journal of hematology and infectious diseases2021

Implementation of Microelimination Strategy in Eradication of Chronic Hepatitis C Infection in Patients with Hemophilia in the Northern region of Serbia: Is Eradication Possible?

Maja Ružić, Natalija Rajić, Milotka Fabri, Ivana Urošević, Marina Dragičević Jojkić, Tomislav Preveden, Maria Pete, Nebojša Rajić

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Maja RužićFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Infectious Diseases.
Natalija RajićFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Infectious Diseases.
Milotka FabriFaculty of Pharmacy of Novi Sad, Business Academy University in Novi Sad.
Ivana UroševićFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Hematology.
Marina Dragičević JojkićFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Hematology.
Tomislav PrevedenFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Infectious Diseases.
Maria PeteFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Infectious Diseases.
Nebojša RajićFaculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Clinic for Hematology.
University of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreating HCV in people with hemophilia prevents the development of end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) and greatly increases the quality of life for people living with hemophilia. There are many obstacles in reaching the WHO goal of globally eradicating HCV by 2030, mainly its scale, complexity, and implementation. That is why many countries have implemented a micro-elimination strategy: a pragmatic elimination approach in populations with the most efficacy. The aim of this publication is to present the morbidity and mortality rates, the clinical course and treatment outcomes of chronic HCV infection in people with hemophilia (PwH), as well as to show an example of a successfully conducted HCV micro-elimination strategy among people with hemophilia in the Province of Vojvodina.

methodsA retrospective, single-center study, performed using medical documentation of all registered PwH in the Clinical Center of Vojvodina from 1994. until 2020. It included 74 hemophilia patients, out of which 32 were patients with hemophilia and chronic HCV infection.

resultsThe mean age of HCV-positive positive people with hemophilia (PwH) was 42.3 years, with the duration of infection of 30-35 years. Co-infection with HIV was observed in 6.25% of cases. Furthermore, 18.75% of patients had spontaneous HCV elimination, and 75% were treated with antiviral protocols. Cirrhosis developed in 21.87% with an incidence rate of 0.6 per 100 patient-years. After treatment with Pegylated IFN and ribavirin (RBV), 58.3% achieved SVR. Side effects of IFN-based therapy regimens were recorded in 20.8% of treated (PwH). In 37.5% PWH, DAA protocols were administered, and these patients achieved SVR. HCV- PwH have a statistically higher mortality rate than non-infected people with hemophilia. Among the HCV-positive PwH, hemophilia-related deaths were 6.25%, and HCV-related deaths were 9.37%. Currently, in the Registry of PwH in Vojvodina, there are no patients with active HCV infection.

conclusionThe micro-elimination strategy in the subpopulation of PwH was successfully implemented in Vojvodina by hematologists and infectious diseases specialists in close collaboration.

Indexed as

Antiviral therapyHemophiliaHepatitis CHepatocellular carcinomaHereditary blood disordersViral hepatitis

Identifiers

PMID34527210
PMCPMC8425382
OpenAlexW3198811009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.